Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.70 |
| ▸ | PKM | P14618 | 4/20 | 0.58 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 2/20 | 0.53 |
| ▸ | IDH1 | O75874 | 1/20 | 0.51 |
| ▸ | PKLR | P30613 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30435230 | 0.89 | AHR (0.66) | AHRPKMSRD5A1MAOAMAOB | |
| SCHEMBL7492910 | 0.89 | AHR (0.66) | AHRPKMSRD5A1MAOAMAOB | |
| SCHEMBL3307966 | 0.86 | KIF11 (0.68) | AHRPKMMAOAMAOBNPC1 | |
| SCHEMBL14698684 | 0.86 | AHR (0.59) | AHRPKMSRD5A1MAOAMAOB | |
| SCHEMBL2395389 | 0.85 | AHR (0.70) | AHRPKMSRD5A1MAOAMAOB | |
| SCHEMBL29754265 | 0.85 | AHR (0.70) | AHRPKMSRD5A1MAOAMAOB | |
| SCHEMBL154614 | 0.82 | AHR (1.00) | AHRMAOBCMA1PDE3BPDE3A | |
| SCHEMBL426336 | 0.81 | NPC1 (0.55) | AHRPKMMAOAMAOBNPC1 | |
| SCHEMBL10464886 | 0.81 | SMYD3 (0.53) | AHRPKMSRD5A1MAOAMAOB | |
| SCHEMBL10461645 | 0.80 | PKM (0.51) | AHRPKMMAOAMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | FAXIAN THERAPEUTICS, LLC | 2024-05-16 | — | — | US | disclosed |
| CN-111587239-B | Method for producing lactam compound and lactam compound produced by the method | 基础科学研究院 | 2024-04-02 | — | — | CN | disclosed |
| EP-4288442-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | Faxian Therapeutics, LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230192643-A1 | DIHYDROQUINOLINONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2022170198-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | FAXIAN THERAPEUTICS, LLC (US) | 2022-08-11 | — | — | WO | disclosed |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-11046661-B2 | Method for producing lactam compound, and lactam compound produced thereby | INSTITUTE FOR BASIC SCIENCE (KR) | 2021-06-29 | — | — | US | disclosed |
| US-11046661-B2 | Method for producing lactam compound, and lactam compound produced thereby | INSTITUTE FOR BASIC SCIENCE (KR) | 2021-06-29 | — | — | US | disclosed |
| US-20200331871-A1 | METHOD FOR PRODUCING LACTAM COMPOUND, AND LACTAM COMPOUND PRODUCED THEREBY | INSTITUTE FOR BASIC SCIENCE (KR) | 2020-10-22 | — | — | US | disclosed |
| US-20200331871-A1 | METHOD FOR PRODUCING LACTAM COMPOUND, AND LACTAM COMPOUND PRODUCED THEREBY | INSTITUTE FOR BASIC SCIENCE (KR) | 2020-10-22 | — | — | US | disclosed |
| WO-2003057672-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| EP-0162776-B1 | HETEROCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS USEFUL AS ALDOSE REDUCTASE INHIBITORS CONTAINING THEM | LABORATOIRES UPSA (FR) | 1989-04-19 | — | — | EP | disclosed |
| US-4755509-A | Heterocyclic aldose reductase inhibitors and methods of using them | Carbipem (FR) | 1988-07-05 | — | — | US | disclosed |
| EP-0040418-B1 | PROCESS FOR PREPARING AN 1H-INDAZOL-3-YLACETIC ACID DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-07-03 | — | — | EP | disclosed |
| EP-0003532-B1 | OMEGA-(2-(N-LOWER ALKYL-BENZAMIDO)-PHENYL)-ALKANOIC ACIDS, THEIR USE AND PREPARATION, AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-04-28 | — | — | EP | disclosed |
| US-4322439-A | ω-[2-(N-Lower alkyl-benzamido)-phenyl]-alkanoic acids, their use, and medicaments containing them | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1982-03-30 | — | — | US | disclosed |
| EP-0040418-A1 | Process for preparing an 1H-indazol-3-ylacetic acid derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-11-25 | — | — | EP | disclosed |
| EP-0008759-A2 | New process for preparing an 1H-indazol-3-ylacetic acid derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-03-19 | — | — | EP | disclosed |
| WO-1979000586-A1 | W-(2-N-LOWER ALKYL-BENZAMIDO)-PHENYL)-ALKANOIC ACIDS,THEIR USE AND PREPARATION,AND MEDICAMENTS CONTAINING THEM | BYK GULDEN LOMBERG CHEM FAB (DE) | 1979-08-23 | — | — | WO | disclosed |
| EP-0003532-A1 | Omega-(2-(N-lower alkyl-benzamido)-phenyl)-alkanoic acids, their use and preparation, and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | USP7, USP28, USP1 | AHR 1258/4885PKM 3167/4885SRD5A1 3133/4885 |
| US-20200331871-A1 | METHOD FOR PRODUCING LACTAM COMPOUND, AND LACTAM COMPOUND PRODUCED THEREBY | SQLE, COASY, DHPS | AHR 2822/4885PKM 2748/4885SRD5A1 469/4885 |
| US-20230192643-A1 | DIHYDROQUINOLINONES FOR MEDICAL TREATMENT | CRBN, RBX1, ADRM1 | AHR 2934/4885PKM 3459/4885SRD5A1 2615/4885 |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | AHR 1519/4885PKM 2326/4885SRD5A1 3980/4885 |
| US-11046661-B2 | Method for producing lactam compound, and lactam compound produced thereby | SQLE, COASY, DHPS | AHR 2822/4885PKM 2748/4885SRD5A1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.